Aytu BioScience, Inc. (NASDAQ: AYTU) today announced that the Company has exclusively licensed Zolpimist™ (zolpidem tartrate oral spray) in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Management Comments

Aytu BioScience Enters $1.8 Billion U.S. Prescription Sleep Aid Market with Exclusive License to Zolpimist(TM) to Expand Company's Commercial-Stage Product PortfolioJune 13, 2018 8:06 AM